Several other equities analysts have also commented on SNNA. ValuEngine lowered Sienna Biopharmaceuticals from a buy rating to a hold rating in a report on Thursday, January 24th. Zacks Investment Research raised Sienna Biopharmaceuticals from a hold rating to a buy rating and set a $3.00 target price on the stock in a report on Tuesday, January 22nd. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Sienna Biopharmaceuticals presently has an average rating of Hold and a consensus price target of $21.67.
Sienna Biopharmaceuticals stock opened at $1.32 on Monday. Sienna Biopharmaceuticals has a twelve month low of $1.11 and a twelve month high of $18.05. The company has a debt-to-equity ratio of 0.90, a quick ratio of 2.07 and a current ratio of 2.61. The firm has a market cap of $41.02 million, a PE ratio of -0.37 and a beta of 3.40.
Sienna Biopharmaceuticals (NASDAQ:SNNA) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.67) earnings per share for the quarter. Analysts predict that Sienna Biopharmaceuticals will post -0.99 EPS for the current year.
A number of large investors have recently bought and sold shares of the stock. Northern Trust Corp increased its holdings in Sienna Biopharmaceuticals by 2.5% in the fourth quarter. Northern Trust Corp now owns 173,341 shares of the company’s stock valued at $402,000 after buying an additional 4,230 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Sienna Biopharmaceuticals by 18.1% in the third quarter. Bank of New York Mellon Corp now owns 43,627 shares of the company’s stock valued at $647,000 after buying an additional 6,682 shares during the last quarter. Geode Capital Management LLC increased its holdings in Sienna Biopharmaceuticals by 4.1% in the fourth quarter. Geode Capital Management LLC now owns 168,219 shares of the company’s stock valued at $390,000 after buying an additional 6,699 shares during the last quarter. Rhumbline Advisers increased its holdings in Sienna Biopharmaceuticals by 52.9% in the fourth quarter. Rhumbline Advisers now owns 19,377 shares of the company’s stock valued at $45,000 after buying an additional 6,702 shares during the last quarter. Finally, Paloma Partners Management Co purchased a new position in Sienna Biopharmaceuticals in the fourth quarter valued at $28,000. 33.08% of the stock is currently owned by hedge funds and other institutional investors.
About Sienna Biopharmaceuticals
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of pruritus or itch associated with psoriasis, as well as for psoriasis; and SNA-125, a topical janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
See Also: Moving Average (MA)
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.